Study to Evaluate the Relative Bioavailability of Two Risankizumab Drug Product Presentations in Healthy Volunteers.
Completed · Phase 1 · NCT05567029
Conditions: Healthy Volunteers
At a glance
- Research payments reported, 2025
- $4,487
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 198
About the trial
- Sponsor
- AbbVie
- Tested
- Risankizumab Dose A (drug), Risankizumab Dose B (drug)
- Dates
- Started 2022-09-28; completion 2023-04-20
- Results posted
- Not yet
This study will assess how safe risankizumab is and how risankizumab moves through the body of adult healthy participants. Adverse Events will be assessed. Risankizumab is an investigational drug being developed for the treatment of Crohn's Disease. Participants are randomly assigned to one of the 2 treatment groups. Approximately 198 adult healthy volunteers will be enrolled in at least 4 sites across the world. All participants will receive risankizumab as subcutaneous injections in one of the 2 different formulations. There may be higher burden for participants in this trial. Participants will be confined for 10 days and followed up for 140 days. Adverse Events and blood tests will be …
From ClinicalTrials.gov, last updated 2023-04-28. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $4,487 in research payments for this study in 2025 (1 payments).
Products named: Skyrizi
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Ppd Development LP $4,487
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.